Pages

Wednesday, September 07, 2022

The Biosimilar Boom and the Coming Humira Price War (Video)

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. Prices are dropping while adoption accelerates. In many therapeutic areas, biosimilars’ market share is approaching 80%. In the video below, I review these developments and discuss lessons from the launch of Semglee, the first interchangeable insulin.

I also offer some thoughts on 2023 and 2024. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. Some—but likely not all—of these products will have interchangeability with Humira.

The video is excerpted from last month’s Specialty Drugs Update: Trends, Controversies, and Outlook video webinar. During the webinar, I speculated that net prices in the Humira category will be 70% or more below today’s prices. If you missed the live event, you can register to watch a replay and download the full slide deck.

Despite these positive recent developments, the just-passed Inflation Reduction Act (IRA) seems likely to disrupt the biosimilar market by altering launch strategies. However, the IRA won’t affect the coming Humira price war.

Enjoy!

Click here if you can’t see the video below.



No comments:

Post a Comment